Kerrie Brady Email

CEO & President . OcuTerra Therapeutics

Boston, MA

Location

LinkedIn

Current Roles

Employees:
15
Revenue:
$1.2M
About
Non-Invasive, Transformational Approach to Treating Retinal Disease. OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity
OcuTerra Therapeutics Address
50 Milk Street
Boston, MA
United States
OcuTerra Therapeutics Email